Alkermes’ alixorexton secures FDA and EC orphan designations

Alkermes’ alixorexton secures FDA and EC orphan designations is a pharma and life sciences industry update from Clinical Trials Arena. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Source: Clinical Trials Arena